Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 336

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 336
---
2, Iris filed with the Secretary of State of the State of Delaware the Extension Amendment to Iris’s amended and restated certificate of incorporation to change the date by which Iris

<div align='center'>177</div>

TABLE OF CONTENTS

must consummate a business combination from March 9, 2023 to June 9, 2023 (subject to an additional three month extension at the discretion of the Iris Board). Iris’s stockholders approved the Extension Amendment at the special meeting on December 20, 2022.

In connection with the special meeting, stockholders holding 26,186,896 shares of Iris Class A Common Stock properly exercised their right to redeem their shares (and did not withdraw their redemption) for cash at a redemption price of approximately $10.08 per share, for an aggregate redemption amount of $263,963,913. Following such redemptions, 1,413,104 shares of Iris Class A Common Stock remained outstanding in the trust.

On April 26, 2023, Dr. Shashibhushan Borade, an Audit Committee member, notified Iris of his intent to resign as a member of the Iris Board, effective April 26, 2023. Dr. Borade’s decision to resign was not the result of any dispute or disagreement with Iris on any matter relating to Iris’s operation, policies (including accounting or financial policies) or practices.

On May 30, 2023, the Iris Board held a meeting and: (i) extended the date by which Iris must consummate a Business Combination for a three month period from June 9, 2023 to September 9, 2023, and (ii) appointed Nicholas Fernandez to serve as a director. Consistent with this extension by the Iris Board, the parties to the Business Combination Agreement amended the Business Combination Agreement on June 1, 2023, to extend the date by which the parties thereto can terminate the Business Combination Agreement if the transaction has not closed by that date from June 7, 2023, to September 30, 2023.

On August 16, 2023, Iris filed a preliminary proxy statement with the SEC containing a proposal to stockholders to amend the Iris Certificate of Incorporation to, among other things, extend the date by which Iris must consummate a business combination from September 9, 2023, to March 9, 2024. On August 14, 2023, the parties to the Business Combination